The European Union has approved GSK's drug Blenrep to treat relapsed or treatment-resistant forms of a cancer affecting blood ...

GSK (NYSE:GSK) announced on Thursday that EU regulators approved two combination therapies involving its antibody drug ...

The U.S. Food and Drug Administration's panel of independent advisers voted on Thursday against approval of GSK's blood cancer drug Blenrep for use in combination with other treatments. The panel vote ...

(Alliance News) - GSK PLC on Thursday said its Blenrep blood cancer treatment has been approved in Europe, as it awaits a final decision from the US regulator. The London-based pharmaceutical firm ...

In a surprise, advisers to the Food and Drug Administration on Thursday voted that the risks tied to a blood cancer drug from GSK outweighed the benefits it had demonstrated in trials, as concerns ...

GSK (GSK) stock slips as FDA advisors vote against the approval of a combination regimen involving thecompany's blood cancer drug Blenrep. Read more here.

GSK shares fell after a Food and Drug Administration advisory committee voted against approval of the company’s Blenrep drug, a setback for its bid to reintroduce the blood-cancer treatment in ...

The FDA oncologic drugs advisory committee voted against the approval of GSK’s blood cancer treatment Blenrep, delivering a setback to the drugmaker’s efforts to reintroduce the drug to the U ...

The U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) voted against the overall benefit/risk profile at the proposed dosage of GSK plc’s (NYSE: GSK) Blenrep ...

The U.S. Food and Drug Administration's staff reviewers on Tuesday raised safety concerns that GSK's blood cancer drug Blenrep, when used in combination with other treatments, may cause eye damage in ...

The Food and Drug Administration's oncologic drugs advisory committee voted against approval of GSK's blood cancer drug Blenrep. The British pharmaceutical company said Thursday combinations for ...